ARWR Overview

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is82.00 USD with a low forecast of 35.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Arrowhead Pharmaceuticals Inc revenue for the last quarter amounts to 264.03M USD, increased 10461.32

Arrowhead Pharmaceuticals Inc. EPS for the last quarter amounts to 0.22 USD, decreased -115.83

Arrowhead Pharmaceuticals Inc (ARWR) has 711 emplpoyees as of March 30 2026.

Today ARWR has the market capitalization of 8.09B USD.